The battle over 'scope creep' and who gets to be called 'doctor'

StephanieW.EdmondsandGinnyL.Ryanarebothdoctors.Edmonds,aregisterednurse,hasaPh.D.;Ryanisatraditional FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida




comprehensive

author：fashion    Page View：4619

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

advertisement

Featured Speakers

  • Irena Melnikova, Ph.D., partner, Pfizer Ventures
  • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
  • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Young boy dies in trial for Pfizer Duchenne gene therapy
Next article： Hollywood unions extend contract negotiations for actors